Clinical Trial Update: A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas [Phase 2]

View source ↗

Summary

Phase 2 open-label, single-arm trial evaluating a JAK1 inhibitor for large inflammatory hepatocellular adenomas is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Hepatocellular Adenoma

Drugs mentioned

• JAK1 inhibitor

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Inflammatory Hepatocellular Adenoma | Phase 2 | Status: RECRUITING